Gilead Sciences

News

AZ, Daiichi’s TROP2 drug hits the mark in lung cancer

AstraZeneca and partner Daiichi Sankyo have their first phase 3 data for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) – in lung cancer –

News

Gilead, Teva cleared in $3.6bn ‘pay-for-delay’ trial

The jury in a California court has sided with Gilead Sciences and Teva in a lawsuit that accused the drugmakers of conspiring to delay the launch of generic versions of th

News

ASCO: TIGIT returns with Roche, Gilead data

A year ago, enthusiasm for a new generation of cancer immunotherapies targeting TIGIT started to wane, after Roche’s tiragolumab was hit by two

News

XinThera buy builds Gilead’s cancer, inflammation pipeline

Gilead Sciences has bulked up its early-stage R&D portfolio with an agreement to buy XinThera, adding drugs targeting PARP for oncology and MK2 for inflammatory diseas

News

Gilead emerges victorious from HIV PrEP patent trial

A US court has sided with Gilead Sciences in a dispute with the US government centred on the use of HIV medicines for pre-exposure prophylaxis.

News

After FDA rejection, Gilead nears full EU nod for hep D drug

Gilead Sciences is on the brink of getting full approval for the first drug for hepatitis D virus (HDV) in the EU, after getting a positive opinion from the EMA’s human me

AZ, Daiichi’s TROP2 drug hits the mark in lung cancer

Gilead, Teva cleared in $3.6bn ‘pay-for-delay’ trial

ASCO: TIGIT returns with Roche, Gilead data

XinThera buy builds Gilead’s cancer, inflammation pipeline

Gilead emerges victorious from HIV PrEP patent trial

After FDA rejection, Gilead nears full EU nod for hep D drug

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

Gilead Sciences

Editor's Picks